<DOC>
	<DOCNO>NCT01078402</DOCNO>
	<brief_summary>This non-interventional , post-marketing , observational study ( PMOS ) Humira ( adalimumab ) prescribe usual manner accordance term local marketing authorization regard dose , population indication . No data currently exist characterize patient population prescribe Humira Eastern Europe . Further , important establish clinical outcome tolerability Humira Eastern European patient , well compliance Humira treatment , particular acceptability self-injection , may influence routine clinical practice .</brief_summary>
	<brief_title>EValuation HumIRAÂ® Patients With Active Rheumatoid Arthritis , Psoriatic Arthritis Ankylosing Spondylitis EASTern European Countries</brief_title>
	<detailed_description>This PMOS conduct prospective , single-arm , multicountry , multicenter format . The assignment patient Humira decide advance protocol fall within current practice . The prescription Humira clearly separate decision include patient study . No additional procedure ( standard care ) shall apply patient . As study observational nature , follow-up interventional left judgment physician within 14-17 month period ( include tuberculosis ( TB ) screen prophylaxis , indicate ) , define survey patient . The TB screening period per patient 1-4 week , applicable , TB prophylactic treatment period Humira administration 1 month accordance local guideline . For indicative purpose , follow-up patient entail approximately 7 patient visit period . These visit take place average interval 3 month , apart first visit follow TB screen . The first visit follow introduction Humira final visit require intercurrent event . If treatment Humira discontinue , standard practice review patient period 70 day 5 half-lives follow intake last dose physician-prescribed treatment . If physician decides permanently discontinue Humira end plan observational period 13 month , reason discontinuation new treatment regimen prescribe , applicable , document . The next routine follow-up visit termination visit patient PMOS .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Adult patient active RA , PsA AS Humira therapy indicate accord local product label meet follow criterion : Are newly prescribe Humira therapy ( prior history treatment Humira ) , include patient infliximab etanercept treatment history OR Completed Abbott sponsor interventional clinical trial continue treatment commercial Humira thereafter . Patients treat treated drug risk interaction Humira ( see Humira Summary Product Characteristics ) Patients currently participate another clinical trial Patients diagnosis active tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Treatment compliance tolerability Humira patient</keyword>
	<keyword>Eastern European country</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Ankylosing Spondylitis</keyword>
	<keyword>Evaluation clinical outcome</keyword>
</DOC>